| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Email: |
doncunbiosci@gmail.com |
| Products Intro: |
Product Name:PF03715455
Purity:98% HPLC Package:100mg；250mg；1g
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:PF-03715455
CAS:1056164-52-3
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
PF-03715455 manufacturers
- PF-03715455
-
- $2.00 / 100kg
-
2025-10-13
- CAS:1056164-52-3
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | PF-03715455 Basic information |
| Product Name: | PF-03715455 | | Synonyms: | PF-03715455;Urea, N-[1-(3-chloro-4-hydroxyphenyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[[2-[[3-[2-[(2-hydroxyethyl)thio]phenyl]-1,2,4-triazolo[4,3-a]pyridin-6-yl]thio]phenyl]methyl]-;PF03715455,PF 03715455;1-(3-(tert-Butyl)-1-(3-chloro-4-hydroxyphenyl)-1H-pyrazol-5-yl)-3-(2-((3-(2-((2-hydroxyethyl)thio)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)thio)benzyl)urea | | CAS: | 1056164-52-3 | | MF: | C35H34ClN7O3S2 | | MW: | 700.27 | | EINECS: | | | Product Categories: | | | Mol File: | 1056164-52-3.mol |  |
| | PF-03715455 Chemical Properties |
| Melting point | 220 °C | | density | 1.39±0.1 g/cm3(Predicted) | | pka | 7.45±0.20(Predicted) |
| | PF-03715455 Usage And Synthesis |
| Uses | PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2]. | | in vivo | PF-03715455 treatment shows that the Vss and T1/2 are 0.19 L/kg, 1 hour, respectively[2]. | Animal Model: | Male CD Sprague Dawley rats (300-450 g)[2] | | Dosage: | 1 mg/kg | | Administration: | I.v. (Pharmacokinetic Analysis) | | Result: | The Vss, and T1/2 were 0.19 L/kg, 1 hour, respectively.
|
| | IC 50 | p38α: 0.88 nM (IC50); p38β: 23 nM (IC50) | | References | [1] Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. DOI:10.1517/13543784.2015.1006358
[2] Millan DS, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem. 2011 Nov 24;54(22):7797-814. DOI:10.1021/jm200677b |
| | PF-03715455 Preparation Products And Raw materials |
|